

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

1. (Currently amended) A recombinant MVA containing and capable of expressing one or more DNA sequences sequence encoding a dengue virus antigens antigenic epitope.

2-34. (Canceled).

35. (New) The recombinant MVA according to claim 1, wherein the DNA sequence is selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigenic epitope, a DNA sequence encoding a Dengue virus serotype 2 antigenic epitope, a DNA sequence encoding a Dengue virus serotype 3 antigenic epitope, and a DNA sequence encoding a Dengue virus serotype 4 antigenic epitope.

36. (New) The recombinant MVA according to claim 35, wherein the DNA sequence encodes a Dengue virus serotype 2 antigenic epitope.

37. (New) The recombinant MVA according to claim 1, wherein the DNA sequence is selected from the group consisting of a DNA sequence encoding a preM antigen, a DNA sequence encoding an E antigen, or a DNA sequence encoding an NS1 antigen.

38. (New) The recombinant MVA according to claim 1, wherein the DNA sequence is inserted into a site of a naturally occurring deletion within the MVA genome.

39. (New) The recombinant MVA according to claim 38, wherein the DNA sequence is inserted into deletion site II.

40. (New) The recombinant MVA according to claim 1, wherein the DNA sequence is under transcriptional control of the vaccinia virus early/late promoter P7.5.

41. (New) A composition comprising the recombinant MVA according to claim 1 and a pharmaceutically acceptable carrier or diluent.

42. (New) A method for generating an immune response in an animal comprising administering to the animal the composition according to claim 41.

43. (New) The method according to claim 42, wherein the animal is a human.

44. (New) A cell comprising the recombinant MVA according to claim 1.

45. (New) The cell according to claim 44, wherein the cell is a eukaryotic cell.

46. (New) A method for the preparation of a recombinant MVA comprising culturing the cell according to claim 45 under suitable conditions and isolating the recombinant viral particles.